UniQure belongs to the tech sector. This company delivers curative gene therapies that could transform the lives of patients. The stock’s shares have tumbled down by 44% to $40 year-to-date, not much higher than its 52-week low of $36.20. However, analysts still have high hopes for it.
SVB Leerink’s analyst Joseph Schwartz affirmed that shares struggled after the company agreed to give licensing rights for AMT-061, gene therapy for Hemophilia B, to CSL Behring. But the analyst pointed out that uniQure currently shifts focus to next-in-line AMT-130, which is AAV5 gene therapy for Huntington’s Disease (HD).
With the M&A premium now out of stock, its shares’ current level offers an attractive buying opportunity for those investors interested in the firm’s up and coming CNS gene therapies and internal manufacturing, as well as robust intellectual property and knowhow – stated Schwartz.
Furthermore, according to its agreement with CSL Behring, uniQure will work to complete the pivotal Phase 3 HOPE-B trial and manufacturing process validation, along with the manufacturing supply of AMT-061.
The management declared that 26-week Factor IX data from all 54 patients enrolled in the trial is still on track. In addition, they will release topline data from the pivotal trial by YE20. In a Phase 2b dose-confirmation study, the company reported a 41% FIX activity out to one year.
Thus far, HOPE-B is progressing according to plan. UniQure has continued its manufacturing process validation work ahead of the BLA/MAA submissions in the U.S. and EU in 2021.
As part of the deal, uniQure is eligible to receive more than $2 billion, including a $450 million upfront cash payment from CSL Behring. So, the company is well funded to rapidly advance CNS assets, including AMT-130 and AMT-150.
Considering that, Schwartz attached the stock a $67 price target, suggesting 68% upside potential from current levels. Wall Street also gave uniQure a strong-buy rating, setting a $69.89 average price target, which indicates 75% upside potential.
Key Points: AUD/JPY broke below a rising wedge, signalling possible bearish momentum, with immediate resistance at 103.00 and support at…
Key Points EUR/JPY Rises to 168.25: Strengthened by robust Eurozone economy and steady ECB policy. Eurozone GDP Grew by 0.3%…
Key Points: Nio's shares hit 44.20 HKD, up 20%, with electric vehicle deliveries up 134.6% year-on-year to 15,620. BYD leads…
Key Points: Ethereum fell sharply from $3,355 to a low of $2,813, reflecting high volatility and sensitivity to market dynamics.…
Key Points Nikkei 225 slightly fell by 0.1%, while the Hang Seng index surged by 2.4%. USD/JPY increased slightly, highlighting…
Key Points: Gold prices rose on MCX India to ₹71,278/10 gm and COMEX US to $2,328/oz. The US Dollar Index…
This website uses cookies.